Literature DB >> 23517919

Gestational angiogenic biomarker patterns in high risk preeclampsia groups.

Sharon E Maynard1, Sybil L Crawford, Susanne Bathgate, Jing Yan, Laura Robidoux, Melissa Moore, Tiffany A Moore Simas.   

Abstract

OBJECTIVE: Several conditions are associated with increased preeclampsia (PE) risk. Whether altered maternal angiogenic factor levels contribute to risk in these conditions is unknown. Our objective was to compare angiogenic biomarker patterns in high-risk pregnancies and low-risk controls. STUDY
DESIGN: We conducted a planned secondary analysis of a 2-center observational study of angiogenic biomarkers in high-risk women. A total of 156 pregnant women with a PE risk factor and 59 low-risk controls were studied. Serial maternal serum samples were collected during 3 gestational windows: 23-27 weeks, 28-31 weeks, and 32-35 weeks. Soluble fms-like tyrosine kinase 1 (sFlt1), soluble endoglin (sEng), and placental growth factor (PlGF) were measured by enzyme-linked immunosorbent assay. Geometric mean angiogenic biomarker levels and angiogenic ratio (sFlt1 + sEng):PlGF were compared with low-risk controls for each risk group, at each gestational window.
RESULTS: Gestational biomarker patterns differed in PE risk groups as compared with low-risk controls. Women with multiple gestations had markedly higher sFlt1 and sEng at all gestational windows. Women with prior PE had higher sFlt1 and angiogenic ratio, and lower PlGF, from 28 weeks onward. Women with chronic hypertension had significantly higher angiogenic ratio for all 3 gestational windows, but differences disappeared when women with PE were excluded. Obese and nulliparous women had significantly lower PlGF, but no differences in the angiogenic ratio.
CONCLUSION: High-risk groups have altered angiogenic biomarker patterns compared with controls, suggesting that altered production or metabolism of these factors may contribute to PE risk, particularly in women with multiple gestations and prior PE.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  PlGF; angiogenic factors; preeclampsia; sEng; sFlt1

Mesh:

Substances:

Year:  2013        PMID: 23517919     DOI: 10.1016/j.ajog.2013.03.017

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

1.  Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention.

Authors:  Gaea S Moore; Amanda A Allshouse; Virginia D Winn; Henry L Galan; Kent D Heyborne
Journal:  Pregnancy Hypertens       Date:  2015-06-23       Impact factor: 2.899

Review 2.  Sleep Disordered Breathing, a Novel, Modifiable Risk Factor for Hypertensive Disorders of Pregnancy.

Authors:  Laura Sanapo; Margaret H Bublitz; Ghada Bourjeily
Journal:  Curr Hypertens Rep       Date:  2020-03-12       Impact factor: 5.369

3.  Preeclampsia in high risk women is characterized by risk group-specific abnormalities in serum biomarkers.

Authors:  Torri D Metz; Amanda A Allshouse; Anna G Euser; Kent D Heyborne
Journal:  Am J Obstet Gynecol       Date:  2014-04-23       Impact factor: 8.661

4.  Low-dose aspirin for pre-eclampsia prevention in twins with elevated human chorionic gonadotropin.

Authors:  A G Euser; T D Metz; A A Allshouse; K D Heyborne
Journal:  J Perinatol       Date:  2016-04-07       Impact factor: 2.521

5.  Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.

Authors:  Steven J Korzeniewski; Roberto Romero; Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Chong Jai Kim; Yeon Mee Kim; Jung-Sun Kim; Bo Hyun Yoon; Sonia S Hassan; Lami Yeo
Journal:  Am J Obstet Gynecol       Date:  2015-12-11       Impact factor: 8.661

6.  Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta.

Authors:  Carlos A Labarrere; Hector L DiCarlo; Elaine Bammerlin; James W Hardin; Yeon M Kim; Piya Chaemsaithong; David M Haas; Ghassan S Kassab; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2016-12-27       Impact factor: 8.661

Review 7.  The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.

Authors:  Rohan Willis; E B Gonzalez; A R Brasier
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

8.  The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Amy E Whitten; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2016

Review 9.  Pre-eclampsia part 1: current understanding of its pathophysiology.

Authors:  Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Lami Yeo; Roberto Romero
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

10.  ELABELA plasma concentrations are increased in women with late-onset preeclampsia.

Authors:  Bogdan Panaitescu; Roberto Romero; Nardhy Gomez-Lopez; Percy Pacora; Offer Erez; Felipe Vadillo-Ortega; Lami Yeo; Sonia S Hassan; Chaur-Dong Hsu
Journal:  J Matern Fetal Neonatal Med       Date:  2018-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.